Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Valentin Florian Rauca"'
Autor:
Emilia Licarete, Valentin Florian Rauca, Lavinia Luput, Denise Drotar, Ioana Stejerean, Laura Patras, Bogdan Dume, Vlad Alexandru Toma, Alina Porfire, Claudia Gherman, Alina Sesarman, Manuela Banciu
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 8, p 2968 (2020)
Regardless of recent progress, melanoma is very difficult to treat, mainly due to the drug resistance modulated by tumor cells as well as by the tumor microenvironment (TME). Among the immune cells recruited at the tumor site, tumor associated macrop
Externí odkaz:
https://doaj.org/article/2c3865ad451046d7be907ed40155851c
Autor:
Valentin-Florian Rauca, Laura Patras, Lavinia Luput, Emilia Licarete, Vlad-Alexandru Toma, Alina Porfire, Augustin Catalin Mot, Elena Rakosy-Tican, Alina Sesarman, Manuela Banciu
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Abstract Anti-angiogenic therapies for melanoma have not yet been translated into meaningful clinical benefit for patients, due to the development of drug-induced resistance in cancer cells, mainly caused by hypoxia-inducible factor 1α (HIF-1α) ove
Externí odkaz:
https://doaj.org/article/03c6b0e8b4f24848a334855428de8d78
Autor:
Laura Patras, Aura Elena Ionescu, Cristian Munteanu, Renata Hajdu, Andreea Kosa, Alina Porfire, Emilia Licarete, Valentin Florian Rauca, Alina Sesarman, Lavinia Luput, Paul Bulzu, Paul Chiroi, Rares Andrei Tranca, Marta-Szilvia Meszaros, Giorgiana Negrea, Lucian Barbu-Tudoran, Monica Potara, Stefan Szedlacsek, Manuela Banciu
Publikováno v:
Cancer Biology & Therapy. 23:1-16
Autor:
Valentin-Florian Rauca, Emilia Licarete, Lavinia Luput, Alina Sesarman, Laura Patras, Paul Bulzu, Elena Rakosy-Tican, Manuela Banciu
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0202827 (2018)
The major drawback of current anti-angiogenic therapies is drug resistance, mainly caused by overexpression of the transcription factor, hypoxia-inducible factor 1α (HIF-1α) as a result of treatment-induced hypoxia, which stimulates cancer cells to
Externí odkaz:
https://doaj.org/article/d198c2d0301e4be09574cc6fda7b45e2
Autor:
Lavinia Luput, Emilia Licarete, Laura Patras, Alina Sesarman, Laurian Vlase, Manuela Banciu, Vlad Alexandru Toma, Ioan Tomuta, Valentin Florian Rauca, Tibor Casian, Alina Porfire, Nicolae Dragoş, Ioana Stejerean, Marcela Achim, Dana Muntean, Denise Minerva Drotar
Publikováno v:
Cancer Science
5‐Fluorouracil‐based therapy remains the main approach in colorectal cancer, even though there are still some drawbacks, such as chemoresistance. In this study we combined 5‐fluorouracil encapsulated in long‐circulating liposomes with simvast
Autor:
Giorgiana Negrea, Valentin-Florian Rauca, Marta Szilvia Meszaros, Laura Patras, Lavinia Luput, Emilia Licarete, Vlad-Alexandru Toma, Alina Porfire, Dana Muntean, Alina Sesarman, Manuela Banciu
Primary melanoma aggressiveness is determined by rapid selection and growth of cellular clones resistant to conventional treatments, resulting in metastasis and recurrence. In addition, a reprogrammed tumor-immune microenvironment supports melanoma p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e6586521f88f76ebd6333a5535943f4
https://mediatum.ub.tum.de/1657589
https://mediatum.ub.tum.de/1657589
Autor:
Alina Porfire, Alina Sesarman, Dana Muntean, Rareș Ionuț Știufiuc, Cristian Moldovan, Ioan Tomuță, Alin Moldovan, Cristina Barbălată, Valentin Florian Rauca, Manuela Banciu
Publikováno v:
Pharmaceutics
Pharmaceutics, Vol 13, Iss 1526, p 1526 (2021)
Volume 13
Issue 10
Pharmaceutics, Vol 13, Iss 1526, p 1526 (2021)
Volume 13
Issue 10
An increasing number of studies published so far have evidenced the benefits of Simvastatin (SIM) and Doxorubicin (DOX) co-treatment in colorectal cancer. In view of this, the current study aimed to investigate the pharmaceutical development of lipos
Autor:
Lucian Barbu-Tudoran, Laura Patras, Emilia Licarete, Chiroi P, Alina Porfire, Monica Potara, Paul-Adrian Bulzu, Tranca Ra, Lavinia Luput, Valentin Florian Rauca, Negrea G, Alina Sesarman, Hajdu R, Manuela Banciu, Szedlacsek Ss, Munteanu Cva, Artur Ionescu, Meszaros Ms, Kosa Ac
Tailoring extracellular vesicles (EVs) as targeted drug delivery systems to enhance the therapeutic efficacy showed superior advantage over liposomal therapies. Herein, we developed a novel nanotool for targeting B16.F10 murine melanoma, based on EVs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9c26a91f69663f9ca47304737d6e623
https://doi.org/10.20944/preprints202105.0229.v1
https://doi.org/10.20944/preprints202105.0229.v1
Autor:
Alina Porfire, Lavinia Luput, Denise Minerva Drotar, Ioana Stejerean, Bogdan Dume, Emilia Licarete, Vlad Alexandru Toma, Valentin Florian Rauca, Laura Patras, Manuela Banciu, Alina Sesarman, Claudia Gherman
Publikováno v:
International Journal of Molecular Sciences
Volume 21
Issue 8
International Journal of Molecular Sciences, Vol 21, Iss 2968, p 2968 (2020)
Volume 21
Issue 8
International Journal of Molecular Sciences, Vol 21, Iss 2968, p 2968 (2020)
Regardless of recent progress, melanoma is very difficult to treat, mainly due to the drug resistance modulated by tumor cells as well as by the tumor microenvironment (TME). Among the immune cells recruited at the tumor site, tumor associated macrop